RxDoctor Payments Data

Gareth Lema, MD

Retina Specialist · New York, NYNPI 1982802476

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.6%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alimera Sciences, Inc. at 59.1% of the total. Reporting peaked in 2022 at $6,565 and has fallen 90.3% since, to $637 in 2025.

$11,167in general payments, 2019–2025

Across 52 payments — averaging $214.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$7K
  • Lensar, Inc.$1K
  • Bausch & Lomb Americas Inc.$488
  • Alcon$390
  • Dutch Ophthalmic, USA$379
  • AbbVie$342
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$6,10055%
  • Food & beverage$5,04845%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,167 in reported general payments places this provider in the 75th percentile of 99 retina specialist providers in New York.

See all retina specialist providers in New York

Medicare billing

Part B allowed, 2024
$45,669
Medicare patients
120
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac31$11,136
CombiganBrimonidine Tartrate/Timolol18$7,935
Brimonidine Tartrate42$2,636
Prednisolone Acetate39$2,200
Difluprednate14$1,204
Latanoprost59$408
Dorzolamide Hcl31$330
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$329
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$184
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim28$133
Ketorolac Tromethamine11$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$216$11,13631 claims
AbbVieCombigan$342$7,93518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 99 retina specialist providers in New York.

Other retina specialist in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →